RxSight, Inc.

Johnson Fistel Begins Investigation on Behalf of RxSight, Inc. Shareholders

Shareholder rights law firm Johnson Fistel, LLP is investigating whether RxSight, Inc. (NASDAQ: RXST), or any of its executive officers, violated federal securities laws by making false or misleading statements or failing to disclose material information to investors.

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.

Name(Required)

First Last

Email(Required)

Phone(Required)

Estimated Losses(Required)

Where did you see our press release?(Required)

If you selected 'Other' above, please specify below:(Required)

Would you like to receive future case and securities updates from Johnson Fistel, PLLP via email?(Required)

Yes

Would you like to receive information about Johnson Fistel, PLLP's free portfolio monitoring service?(Required)

Yes

By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, PLLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

I Agree

What is this about?

The investigation focuses on whether RxSight misled investors regarding its business outlook and product adoption trends. On July 9, 2025, the company released preliminary financial results for the second quarter of 2025, reporting notable declines in Light Delivery Device (LDD) sales, usage of its light adjustable intraocular lenses (LALs), and total revenue. RxSight also revised its full-year 2025 guidance downward by roughly $42.5 million at the midpoint, citing “[a]doption challenges over the last few quarters” as a key factor behind the slowdown in LDD performance.

What if I have relevant nonpublic information?

Individuals with nonpublic information regarding RxSight should consider assisting with our investigation or exploring options under the SEC Whistleblower Program. Whistleblowers who submit original information to the SEC may, under certain conditions, receive rewards of up to 30% of any successful enforcement action. For more information, contact Jim Baker at (619) 814-4471 or jimb@johnsonfistel.com.

RxSight, Inc.

Johnson Fistel Begins Investigation on Behalf of RxSight, Inc. Shareholders

What is this about?

What if I have relevant nonpublic information?

California

New York

Georgia

Colorado

Idaho